申请人:Pfizer Inc.
公开号:US20150182513A1
公开(公告)日:2015-07-02
The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
本发明涉及一种新型的
羟胺酸衍
生物类,其作为LpxC
抑制剂的用途,更具体地,其用于治疗细菌感染。